Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) - Equities researchers at HC Wainwright decreased their FY2027 EPS estimates for Century Therapeutics in a research report issued to clients and investors on Friday, November 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($0.48) for the year, down from their prior estimate of ($0.47). The consensus estimate for Century Therapeutics' current full-year earnings is ($0.51) per share.
Several other research firms have also recently weighed in on IPSC. Wall Street Zen raised Century Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. Weiss Ratings lowered Century Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Century Therapeutics currently has a consensus rating of "Hold" and a consensus target price of $4.75.
Get Our Latest Analysis on IPSC
Century Therapeutics Stock Down 0.6%
Century Therapeutics stock opened at $1.64 on Tuesday. Century Therapeutics has a 52 week low of $0.43 and a 52 week high of $3.04. The business has a 50-day simple moving average of $1.64 and a 200 day simple moving average of $2.06. The stock has a market cap of $296.95 million, a price-to-earnings ratio of -2.56 and a beta of 1.78.
Century Therapeutics (NASDAQ:IPSC - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.01.
Institutional Investors Weigh In On Century Therapeutics
Institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp bought a new stake in Century Therapeutics in the first quarter worth $29,000. State of Wyoming purchased a new position in shares of Century Therapeutics in the second quarter worth about $82,000. The Manufacturers Life Insurance Company purchased a new position in shares of Century Therapeutics in the second quarter worth about $85,000. Legal & General Group Plc bought a new stake in shares of Century Therapeutics in the 2nd quarter valued at about $108,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Century Therapeutics in the 1st quarter valued at about $108,000. Hedge funds and other institutional investors own 50.20% of the company's stock.
Century Therapeutics Company Profile
(
Get Free Report)
Century Therapeutics is a biotechnology company developing cell-based therapies for cancer and other serious diseases. Its research focuses on allogeneic treatments, which are designed to be produced from donor cells rather than made separately for each patient. The company uses induced pluripotent stem cell technology to create immune cells, including natural killer cells and T cells, that can be engineered to recognize and attack disease. Its work includes developing cell therapies with genetic modifications intended to improve their activity and persistence.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Century Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Century Therapeutics wasn't on the list.
While Century Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.